Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

Northwestern University

Summary

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Eligibility

Age range: 18–70 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Individuals age 18-70 years old with eyelid dermatitis for at least two months * Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) * Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib. * Willing and able participants that provide informed consent * Willing and able participants that comply with study activities Exclusion Criteria: * Self-reported history of allergic response to upa…

Interventions

Drug
Upadacitinib 15 MG
Upadacitinib 15mg daily

Location

Northwestern University Department of Dermatology
Chicago, Illinois
NUderm-research@northwestern.edu

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

Summary

Eligibility

Interventions

Location

Run this study?

Details

Conditions